Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Reexamination Certificate
2006-01-17
2006-01-17
Wang, Shengjun (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
C514S564000, C514S634000, C514S228800
Reexamination Certificate
active
06987129
ABSTRACT:
The present invention provides methods for treating a variety of urogenital disorders, such as, for example, vaginismus, dyspareunia, vulvodynia (including vulvar vestibulitis), interstitial cystitis, nonspecific urethriris (i.e., nonspecific pain and/or burning of the urinary tract) and sexual dysfunctions, such as, for example, female sexual arousal disorders and female sexual orgasmic disorders, using a variety of compounds, including, but not limited to, NO donors, calcium channel blockers, cholinergic modulators, α-adrenergic receptor antagonists, β-adrenergic receptor agonists, phosphodiesterase inhibitors, cAMP-dependent protein kinase activators (e.g., cAMP mimetics), superoxide scavengers, potassium channel activators, estrogen-like compounds, testosterone-like compounds, benzodiazepines, adrenergic nerve inhibitors, antidiarrheal agents, HMG-CoA reductase inhibitors, smooth muscle relaxants, adenosine receptor modulators, adenylyl cyclase activators, endothelin receptor antagonists, bisphosphonates and cGMP-dependent protein kinase activators (e.g., cGMP mimetics).
REFERENCES:
patent: 4421737 (1983-12-01), Ito et al.
patent: 4533540 (1985-08-01), Blank
patent: 4559222 (1985-12-01), Enscore et al.
patent: 4654209 (1987-03-01), Leslie et al.
patent: 4655766 (1987-04-01), Theeuwes et al.
patent: 4681584 (1987-07-01), Gale et al.
patent: 4784857 (1988-11-01), Berry et al.
patent: 5071656 (1991-12-01), Lee et al.
patent: 5565466 (1996-10-01), Gioco et al.
patent: 5595970 (1997-01-01), Garfield et al.
patent: 5686099 (1997-11-01), Sablotsky et al.
patent: 5698589 (1997-12-01), Allen
patent: 5731339 (1998-03-01), Lowrey
patent: 5877216 (1999-03-01), Place et al.
patent: 5958926 (1999-09-01), Garvey et al.
patent: 6165975 (2000-12-01), Adams et al.
patent: 6294517 (2001-09-01), Garvey et al.
patent: 6306841 (2001-10-01), Place et al.
patent: 6331543 (2001-12-01), Garvey et al.
patent: 6417207 (2002-07-01), Garvey et al.
patent: 2325930 (2001-07-01), None
patent: WO 95/05172 (1995-12-01), None
patent: WO 96/27372 (1996-09-01), None
patent: WO 98/586633 (1998-12-01), None
patent: WO 99/21562 (1999-05-01), None
patent: WO 99/66909 (1999-12-01), None
Paavonen ‘Diagnosis and Treatment of Vulvodynia,’ 1995, Annals of Medicine, vol. 27, No, 2, p. 175-181.
Burnett, Arthur L., “Immunohistochemical Description of Nitric Oxide Synthase Isoforms in Human Clitoris,”The Journal of Urology, vol. 158, pp. 75-78, (Jul. 1997).
Palmer, R. M. J., “Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor,”Nature, vol. 327, pp. 524-526, (Jun. 11, 1987).
Peleg, Roni, “Glyceryl trinitrate ointment as a potential treatment for primary vaginismus,”European J. of Obstetrics&Gynecology and Reproductive Biology, 96, pp. 111-112, (2001).
Tollins, Jonathan P., “EDRF and Regulation of Vascular Tone,”Hypertension, vol. 17, No. 6, Part 2, pp. 909-913, (1991).
Walsh, Kathleen E., “Safety and Efficacy of Topical Nitroglycerin for Treatment of Vulvar Pain in Women with Vulvodynia: A Pilot Study,”JGSM, vol. 5, No. 4, pp. 1-7, (Jul./Aug. 2002).
Derwent Acc No. 2001-570957 “Medicament useful for prevention and treatment of sexual dysfunction comprises potassium channel opener solutions and/or Papaverin” CA 2325930A (Chem Investment Ltd.) (Jul. 29, 2001) (Abstr.).
“Sexual Pain Disorder” at http://www.psychologytoday.com/HTDocs/prod/PTOInfo/pto—term—sexpain.asp: printed on Feb. 4, 2004.
“Pain Disorders in Women” at http://www.burnc.bu.edu/Departments/PageMain.asp?Page=6930&DepartmentID=371; printed on Feb. 4, 2004.
“Sexual pain disorders” in Conditions & Treatments—Female Sexual Medicine at http://www.urology.medsch.ucla.edu/fsmc new-site-cond-sexpain.htm; printed on Feb. 4, 2004.
Baggish, M. S. and J. R. Miklos: “Vulvar pain syndrome: A review”;Obstetrical and Gynecological Survey; vol. 50, No. 8; pp. 618-627 (1995).
Butcher, J. “A psychosexual approach to managing dyspareunia”;The Practitioner; vol. 247, pp. 484-495; (Jun. 2003).
Glazer, H.: “Vulvovaginal pain disorders and sexual functioning” at http:www.selfhelpmagazine.com/articles/sex/pain.html; printed on Feb. 4, 2004; (Nov. 3, 2000).
Metts, J. F.: “Vulvodynia and vulvar vestibulitis: Challenges in diagnosis and management”;Am. Fam. Physician, vol. 59, No. 6; pp. 1547-1556; (Mar. 15, 1999).
Ridley, C.M.: “Vulvodynia”;Dermatologic Clinics, vol. 16, No. 4; pp. 775-778; (Oct. 1998).
Walsh, K. E. et al.: “Safety and efficacy of topical nitroglycerin for treatment of vulvar pain in women with vulvodynia: A pilot study”;J.G.S.M.; vol. 5, No. 4; pp. 1-7; (Jul./Aug. 2002).
Welsh, B. et al.: “Management of common vulval conditions”;M.J.A.; vol. 178; pp. 391-395; (Apr. 21, 2003).
Grayson Stephen
Mak Vivien H. W.
Cellegy Pharmaceuticals Inc.
Townsend and Townsend / and Crew LLP
Wang Shengjun
LandOfFree
Compounds and methods for the treatment of urogenital disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds and methods for the treatment of urogenital disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds and methods for the treatment of urogenital disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3567660